
Last week, our CEO Craig Thompson joined fellow neuroscience leaders and investors at the @GoldmanSachs Healthcare Private Company Conference to discuss new approaches to neurodegenerative disorders and share findings from our Phase 3 ARISE study in Parkinson’s disease.







